Medicine, Health & Food

Medicine, Health & Food

Correlation of Vascular Endothelial Growth Factor (VEGF) Immunoexpression with histopathological grade of astrocytoma at the H. Adam Malik General Hospital, Medan.

Pages: 7  ,  Volume: 45  ,  Issue: 1 , January   2020
Received: 24 Jan 2020  ,  Published: 24 January 2020
Views: 22  ,  Download: 0

Authors

# Author Name
1 Eka Bitaria Febrawati
2 Lidya Imelda Laksmi
3 Soekimin

Abstract

Background: Astrocytoma is a neuroepithelial tumor of glial cells consisting of infiltrative tumor cells with increased cellularity in accordance with histopathology grade. Vascular Endothelial Growth factor (VEGF) is one of the important factors in the process of angiogenesis. VEGF plays a role in proliferation, survival, endothelial cell migration and vascular permeability.
Materials and methods: This study is an analytical study with cross-sectional approach with spearman test analysis of 31 samples of paraffin blocks of astrocytoma cases that meet the inclusion criteria then immunohistochemistry examination with VEGF and assessed VEGF expression that will be correlation with histopathology grade of astrocytoma.  
Results: A total of 31 samples showed VEGF expression, 7 cases were astrocytoma grade I, 11 cases were astrocytoma grade II, 5 cases were astrocytoma grade III and 8 cases were grade IV astrocytoma. Statistical analysis has a correlation between VEGF expression with histopathology grade of astrocytoma p = 0.005 (p<0.05) and shows a sufficient relationship with r = 0.448. Conclusions: This study revealed that increased VEGF expression was followed by histopathology grade of astrocytoma.  
Conclusion:   There is a correlation between the immunohistochemistry expression of VEGF  and histopathology grade of astrocytoma, where the increase in VEGF expression is followed by an increase in histopathology grade of astrocytoma                                                                           
Keywords: Astrocytic tumours, Grade histopathology, VEGF

Keywords

  • Astrocytic Tumours
  • grade histopathology
  • VEGF
  • References

    1. Dorsey JF, Salinas RD, Dang M, Basanta MA, Judy KD, Maity A et  al. Cancer of the Central Nervous System. In: Niedurhuber JE, Armitage JO, Kastan MB, Doroshow JH, Tepper JE, Editors. Abeloff’s Clinical Oncology. Sixth Edition. Phildelphia: Elsevier; 2019.p.967-906..

    2. Kumar K, Abbas AK, Aster JC. Buku Ajar Patologi Robbins. Edisi 9. Elsevier; 2017. p.835-799.

    3. Louis DN. WHO Classification and grade of tumours of the central nervous ystem. In: Louis DN, Ohgaki OD, Wiestler WK, Cavenee, Editors. WHO Classification of tumours of the Central Nervous System. Revised 4th Edition. Lyon: IARC; 2016.p.13-12.

    4. Almukhtar ZK, Kmal MS, Alkareem SA. Immunohistochemical expression of Ki 67 & CD 31 in Iraqi patient with Astrocytoma, a clinicophatologica; studies. 2019; p.4085-4077.

    5. Bray F, Ferlay J, Soejomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistic 2018: GLOBOCAN Estimates of incidence and mortality world wide for 36 cancer in 185 countries. 2018; p.424-394.

    6. Ostrom QT, Gittlema H, Truitt G, Bosci A, Kruschko C, Sloan JS. CBTRUS Statistical Report: Primary brain and other Central Nervous System Tumors diagnosed in the United stated in 2011-2015. 2018; 20(S4) p.86-1.

    7. Mutmaima IS, Ihwan A. Karakteristik pasien Astrositoma di RSUP dr. Wahidin Sudirohusodo Makassar periode Januari – Desember2016.2017

    8. Retnani DP, Fauziah D. Ekspresi Vascular Endothelial Growth Factor (VEGF) dikaitkan dengan pertumbuhan tumor dan edema Peritumoral Majalah Patologi.2013; 22(3):p.24-9.

    9. Saragih EB, Indharty SS, Siahaan AM. Hubungan ekspresi VEGF dengan Ki-67 Labeling index pada penderita astrocytoma di RSUP H. Adam Malik Medan. 2017. Tesis Magister FK.USUMedan.

    10. Xu Z.G et al. Correlation between VEGFR2 rs2071559 polymorphism and glioma risk among Chinese population. 2015;8(9):16724-16728.

    11. Kresno SB. Angigenesis. In: Ilmu Dasar Onkologi. 3th ed. Jakarta: Badan Penerbit Fakultas Kedokteran Universitas Indonesia. 2012. P 344-68

    12. Yadaf L, Puri N, rostagi V, Satpute P, Sahma V. Tumour Angiogenesis and Angiogenic inhibitor: A review. Journal of Clinical and diagnostic research.2015;9(6):p.5-1

    13. Rizk MK O, Saied M, E, Maqusod El abd ED. Angiogenesis in astrocytoma: An immunohistochemical study of VEGF, Factor VIII and COX-2 expression. 2016; 6(4) p. 195-188

    14. Roslavtceva VV, Salmina AB, Prokopenko SV, Pozhilenkova, Kobanenko IV,Rezvitskaya GG. The Role of Vascular endothelial Growth Factor in the Regulation of Development and functioning of the Brain: New target molecules for Pharmacotherapy. 2016; 10(4):p.309-300.

    15. Shibuya M. Vascular Endothelial Growth Factor (VEGF) and It’s Receptor (VEGFR) Signaling in Angiogenesis: a Crucial Target for Anti – and pro – AngiogenicTherapies. 2011; 2(12):p.1105-1097.

    16. Yang J, Zhao H, Zhong X. Correlation analysis of the clinicopathological features of glioma and expression of p53 and VEGF. 2017;10(2):p.3606-3611.

    17. Rainer E et al. The prognostic value of {123} vascular endothelial growth factor {123} VEGF in glioma.2018.45: p. 2396-2403.

    18. Vokuda SR, Srinivas BH, Manhugiri VS, Verma SK. Vascular Endothelial Growth Factor as an Angiogenic Marker in Malignat Astrocytoma and Oligodendroglioma: An Indian Scenario. 2017; 11(2)p.7-5

    19. Kraus AJ, Dabbs DJ, Beriwal S, Bhargava R. Semiquantitative immunohistochemistry for estrogen and progesteron receptor : an independent quality assurance study. Modern Path. 2012;25:869-76.

    20. Jurantil et al. Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular group. 2018;p. 9-1

    21. Villanueva GK, Rea DN, Krieger DM. Novel surgical and radiologic risk factors for progression or recurrence of pediatric pilocytic astrocytoma.2019:p.11-1

    22. Brem S et al. Angiogenesis and Brain Tumors Scientific Priciples, Current Therapy and Future Direction in Youmas & Winn. Neurological Surgery. Chapter 116. 2017.p.846-825